Navigation Links
Dr. Paul Billings joins Trovagene's Scientific Advisory Board
Date:11/19/2012

SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of transrenal molecular diagnostics, announced today that Dr. Paul Billings has joined the Company's Scientific Advisory Board. A board certified internist and clinical geneticist, Dr. Paul R. Billings currently serves as Chief Medical Officer at Life Technologies Corporation. Dr. Billings brings extensive expertise and clinical experience in the areas of genomics and molecular medicine.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"We are honored that Dr. Billings will be collaborating with Trovagene," states Antonius Schuh, Ph.D., chief executive officer of Trovagene. "He specializes in improving patient care through expanding the use of medically relevant genomic technologies in clinical settings," he continues, "and his expertise is critical he helps shape policy in the rapidly evolving field of genomic medicine."

Dr. Billings has had a distinguished career as a physician, business executive and researcher. He has authored nearly 200 publications and books on genomic medicine and currently serves on the Scientific Advisory Board of the Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. Most recently, he served as Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. Previously, he was senior vice president for corporate development at Laboratory Corporation of America Holdings (LabCorp). He has been a founder or chief executive officer of companies involved in genetic and diagnostic medicine, including GeneSage Inc., Omicia, Inc. and CELLective Dx Corporation. Dr. Billings has held academic appointments at Harvard Medical School, Stanford School of Medicine and the University of California, Berkeley, and has served as a physician at a number of medical centers throughout the country, including the University of California, San Francisco. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology, also from Harvard University.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.  Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample.  As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges associated with biopsy, as well as the volume limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contact

Trovagene, Inc.    
Charlie Rodi                   
Vice President and Chief Scientific Officer
+1 (858) 952-7670                       
crodi@trovagene.com              
www.trovagene.com                     

 

 

 


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
2. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
3. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
4. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
5. David F. Harty Joins Systech International as Vice President
6. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
7. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
8. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
9. Anthony Creed Joins DDSTUDIO As GM, Experience Design
10. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
11. American Society of Hematology joins European Hematology Association, Patient Groups in Issuing International Call to Action to Alleviate Drug Shortages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
Breaking Medicine News(10 mins):